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Over the past decade we have witnessed major strides in our
ability to use drugs to impede or even reverse the progres-
sion of heart failure (HF). With impressive results from
well-designed clinical trials, several new drugs have been
introduced into the armamentarium against chronic HF,
and evidence-based medicine has emerged as the vehicle by
which we deliver new therapy. However, the construct of
“evidence-based medicine” has three major assumptions: 1)
it assumes a timely and accurate delivery of new knowledge
from research studies to practicing physicians; 2) it assumes
competency of the practicing physicians to adequately “as-
similate” new knowledge and apply this knowledge appro-
priately to their own practice; and 3) it assumes that the
findings from the research studies will apply in real-world
scenarios. With more than 10,000 new randomized con-
trolled trials published in the past decade, it is no small task
for physicians to filter and assimilate detailed, new knowl-
edge.
See page 211
Spironolactone, a nonspecific aldosterone receptor antag-
onist, is an example of a drug that has recently been
“re-introduced” as a treatment for HF, following the posi-
tive results observed in a landmark clinical trial (1). At a
time when high-dose angiotensin-converting enzyme inhib-
itor and beta-adrenergic receptor blockers were at the high
ground of medical therapy for patients with chronic HF, the
Randomized Aldosterone Evaluation Study (RALES) dem-
onstrated a marked mortality reduction of 30% in patients
with advanced HF (New York Heart Association [NYHA]
functional class III to IV) when only a modest dose of 12.5
to 25 mg/day dose of spironolactone was added to these two
classes of drugs (1). Importantly, there was also a dose-
dependent improvement in ventricular remodeling and ex-
ercise tolerance during treatment with spironolactone (2).
As the authors of the RALES study note, spironolactone
should be started at 12.5 mg/day and cautiously increased to
25 mg/day. Patients in the study required frequent follow-
ups so that serum potassium and creatinine levels could be
carefully monitored. The patients who entered RALES
were all NYHA functional class IV or III patients who were
previously class IV.
Since the publication of the RALES trial, it is apparent
that the practicing community has widely embraced spi-
ronolactone to treat patients with HF (3). The RALES trial
was first presented at the American Heart Association 71st
Scientific Session on November 11, 1998. The striking
results sparked an extensive dialogue of how spironolactone
should be incorporated into the treatment of HF. However,
the widespread acceptance of spironolactone was unique, as
this was an old drug, simple to use, and physicians had
experience with it. However, as indicated in the report by
Bozkurt et al. (4) in this issue of the Journal, many patients
who were being treated with spironolactone were quite
dissimilar to the patients in the RALES trial. Bozkurt et al.
(4) noted an increase in complication rates immediately
following the prepublication of the RALES trial in July
1999, including inappropriate patient selection, inaccurate
prescriptions, and poor monitoring of adverse events. In
particular, injudicious use of spironolactone has led to
serious cases of renal insufficiency and hyperkalemia. This
was likely to be particularly a problem in patients with
diabetes and in patients in whom angiotensin-converting
enzyme inhibitor or angiotensin receptor blocker doses were
not adjusted for the concomitant use of spironolactone.
Nonsteroidal anti-inflammatory drugs also complicate the
use of spironolactone. We have witnessed a very similar
experience to Bozkurt et al. (4), albeit completely anecdotal.
The findings from this study uncover an emerging prob-
lem in the current age of polypharmacy and the increasingly
more complex elderly patients. There seems to be an
impediment to the translation of clinical evidence into
real-world practice. It would be naive to simply put blame
on those practicing physicians who have generated these
medical “errors.” Indeed, the key findings from the Institute
of Medicine’s report on medical errors indicate that errors
may often be caused by system failures rather than individ-
ual negligence or incompetence (5). The early adoption of
spironolactone (within the first few months of the publica-
tion) observed by Bozkurt et al. (4) demonstrates the good
intentions of these practicing physicians. The challenge here
is to resolve potential system failures in order to fulfill the
assumptions for an effective practice of evidence-based
medicine. Several issues can be raised from this study.
The first issue is the clarity of the publication. Although
careful dose-finding studies were done before RALES,
especially with regard to the hyperkalemia and renal insuf-
ficiency problems (6), most readers of the RALES study
may not be familiar with these findings and discussions.
Bozkurt et al. (4) have pointed out that diabetic patients
(who are known to be at risk for such adverse outcomes)
were not mentioned in the RALES publication. We all
need to pay more attention to the clarity of the publication,
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particularly regarding the potential impact of patient entry
and exclusion criteria.
The second issue is the limitations of the current para-
digm of acquisition of new knowledge by practicing physi-
cians. Although this was not the first report of adverse
events in using spironolactone following the publication of
the RALES trial (7,8), the authors picked a critical study
period (within the first few months of the prepublication
release of RALES) to amplify the notion that we have to
pay more attention to the “learning curve” phenomenon. As
inappropriate patient selection and application appeared to
be a common theme in these reports (4,8,9), questions can
also be raised as to whether busy physicians were even aware
of the patient selection and dose criteria outlined in the
RALES publication. In fact, a recent Canadian survey of
521 practicing physicians revealed that less than half of the
respondents take the effort to review primary research
studies (either reading the primary publication or indirectly
from published summaries) in an attempt to practice
evidence-based medicine (10). It is conceivable that only a
minority of busy practicing physicians would have carefully
studied the paper (or the accompanying editorial) before
prescribing spironolactone to their patients with HF, al-
though there is no direct evidence to support this. There-
fore, there is a need to rethink how the process of scientific
publication can be better adapted to facilitate appropriate
assimilation of new knowledge. Specialty organizations and
individual specialists should also take more responsibilities
in disseminating clinical evidence to their peers. To extend
this issue further, busy clinicians may not have the appro-
priate time or skills to “assimilate” new knowledge from
published studies. The current paradigm of continuing
medical education and recertification for medical boards
may need to be reconsidered in the setting of the exponen-
tial increase in medical information and the proportionally
less time to learn.
The third issue concerns the expertise of practicing
physicians in applying a new therapeutic strategy to a
patient with HF, especially when there is a relatively small
margin of error. The differences among specialties in the
appropriateness of spironolactone prescriptions have previ-
ously been reported (9). However, this does not directly
translate to the notion that cardiologists and HF specialists
should treat all patients with HF. Instead, the implemen-
tation of a multidisciplinary team approach such as the one
described by the authors should facilitate an effective im-
plementation of a drug such as spironolactone.
Finally, the need for anticipation of potential adverse
events is necessary in any form of therapy, whether old or
new. Patients in real-world practice are universally older,
taking more drugs for more comorbid conditions, and may
have confounding nonmedical issues (such as drug compli-
ance) that affect their clinical outcomes. The false sense of
security in using a well-known drug such as spironolactone
has also likely contributed to its injudicious use and subse-
quent adverse outcomes. New drugs have the luxury of a
wide range of monitoring requirements from the Food and
Drug Administration. We encourage researchers and
policy-makers to install national or local drug utilization
evaluation schemes to learn how to maximize the benefits
and minimize the adverse effects of a new treatment
strategy. For example, a multidisciplinary drug utilization
program has been initiated to monitor the use of neseritide
at our institution, and we have carefully examined the
indications, outcomes, and adverse effects for the first 100
patients. Such monitoring or surveillance programs require
time, effort, and a team approach, but can allow objective
evaluation of safety and efficacy of a new treatment strategy.
Taking care of patients is the doctor’s greatest privilege.
As physicians, we should take great care in understanding
the benefits and risks of every therapeutic maneuver that we
perform. As researchers, we should acknowledge that the
publication of our findings is only the end of the beginning,
and the ultimate goal should only be our patients’ well-
being. All’s well only if it ends well.
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